Russia’s experimental coronavirus vaccine Sputnik-V shows the efficacy of 91.4 per cent, a press release said on Monday citing data analysis of the final control point of clinical trials.
Russia’s experimental coronavirus vaccine Sputnik-V shows the efficacy of 91.4 per cent based on data analysis of the final control point of clinical trials. Earlier this year, Russia became the first country in the world to approve a Covid-19 vaccine- Sputnik-V.
According to a press release, the final control point analysis of data obtained 21 days after administering the first dose of Sputnik-V confirmed the efficacy of 91.4 per cent. In a statement, researchers at the Gamaleya Institute said the results are based on data from 22,714 participants in the trial. The results were published after 78 confirmed cases of Covid-19 were reported among the group.
“Calculation was based on the analysis of data of volunteers (n = 22 714) who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point of 78 confirmed cases in accordance with the Phase III clinical trials protocol,” the release went on to add.
According to the official website of Sputnik-V, the “advance to the third and final statistically significant representative control point allowed for the final proof of the efficacy of the vaccine of over 90 per cent.”
Claiming that the experimental vaccine’s efficacy against severe cases of Covid-19 was 100 per cent, the release also said that 20 severe cases were recorded in the placebo group while none were recorded in the vaccine group.
Detailing the protocol of Phase 3 clinical trials of Sputnik-V, the release said the vaccine’s interim efficacy was calculated at three statistically significant representative control points. There were- upon reaching 20, 39 and 78 cases of Covid-19 among volunteers both in the placebo and vaccine groups.
As many as 22,714 volunteers have been vaccinated as part of the double-blind, randomized, placebo-controlled Phase 3 post-registration clinical trials of Sputnik V in Russia.
Credited with developing the double human adenoviral vector-powered Sputnik-V vaccine, Russia’s Gamaleya Center will publish research data corresponding to the clinical trials in the days to come.
“We will definitely share the results achieved with the scientific community and will be happy to discuss them with all interested colleagues,” news agency Reuters quoted Gamaleya Institute’s Denis Logunov as saying.